Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$DARE Q4 '24 Earnings Results & Recap Dare Bioscience reported a comprehensive loss for Q4 2024, with EPS of -$0.61 and revenue of -$0.06M. The company announced plans to launch Sildenafil Cream via the 503B compounding pathway in Q4 2025, alongside the continued pursuit of FDA approval, and expects this strategy to improve its financial condition. The Ovaprene Phase III study experienced a setback due to federal funding uncertainty.
5

Since Post

Full Details

Advertisement|Remove ads.